CoQ10 plus NADH: larger double-blind ME/CFS study
Castro-Marrero J et al. · 2021 · Nutrients
Indexed 2026-11-12.
Reported findings and study design
Reported findings
CoQ10 200 mg plus NADH 20 mg daily for eight weeks, then four weeks of follow-up. The primary endpoint was fatigue impact.
Dose, route and schedule
CoQ10 200 mg plus NADH 20 mg daily for eight weeks, then four weeks of follow-up. The primary endpoint was fatigue impact.
Protocol source ↗ · Original source
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Total fatigue impact | Within the supplement group, total FIS-40 improved at week four (p=0.022). The paper reports parallel fatigue trajectories between groups. | |
| Later assessments | Within-group total fatigue changes at eight weeks and four weeks after treatment were inconclusive (p=0.089 and p=0.071). |
The highlighted four-week improvement was within the active group. Attrition and the absence of a convincing between-group fatigue difference constrain the result.
Source for these results ↗ · Reviewed 2026-11-12
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- The highlighted four-week improvement was within the active group. Attrition and the absence of a convincing between-group fatigue difference constrain the result.
Source access
CoQ10 200 mg plus NADH 20 mg daily for eight weeks, then four weeks of follow-up. The primary endpoint was fatigue impact.
Source reviewed 2026-11-12.
DOI: 10.3390/nu13082658
Citation and original source
Original source: Castro-Marrero J et al.. CoQ10 plus NADH: larger double-blind ME/CFS study Nutrients 2021.
Molekul research summary: https://molekul.io/research/coq10-nadh-mecfs-2021. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry